Goldman Sachs' upgrade of Myriad Genetics from Sell to Buy and the increase in price target from $18 to $25 indicates a positive outlook for the company. This is likely to have a positive short-term impact on MYGN's stock price as investors may react positively to the upgrade and increased price target.